Five important updates in gynecologic cancer

Gynecologic Cancer Awareness Month and Ovarian Cancer Awareness Month are observed in September to educate women about symptoms and the importance of early detection.

“Any woman who experiences unexplained bloating, an upset stomach, an urgency to urinate or abdominal pain for a few weeks should go see a doctor,” Peter Dottino, MD, director of gynecologic oncology at Mount Sinai Health System, said in a press release. “Too often, women are sent to a gastroenterologist or told they’re just aging when experiencing these kinds of symptoms, and by then they have lost valuable time.”

In conjunction with these observances, HemOnc Today presents five updates about screening for and treatment of gynecologic malignancies:

  • The FDA granted regular approval to olaparib (Lynparza, AstraZeneca) tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved complete or partial response to platinum-based chemotherapy. Read more.
  • A second interim analysis of a trial designed to evaluate the addition of fosbretabulin (CA4P, Mateon Therapeutics) to standard therapy for patients with platinum-resistant ovarian cancer showed a small PFS benefit for the combination. Read more.
  • A clinical trial scheduled to evaluate the safety and efficacy of a bag designed to catch cancerous tissue from power morcellation in women undergoing laparoscopic hysterectomies has rekindled debate in the gynecologic community about the controversial procedure. Read more.
  • Clear cell endometrial cancer appeared to have molecular similarities with serous endometrial cancer and endometrioid endometrial cancer, according to a study published in Cancer. Additionally, TAF1 appeared to be a driver mutated gene in clear cell endometrial cancer. Read more.
  • The U.S. Preventive Services Task Force released a draft statement that recommended against screening for ovarian cancer in women who have no signs or symptoms. Read more.

Gynecologic Cancer Awareness Month and Ovarian Cancer Awareness Month are observed in September to educate women about symptoms and the importance of early detection.

“Any woman who experiences unexplained bloating, an upset stomach, an urgency to urinate or abdominal pain for a few weeks should go see a doctor,” Peter Dottino, MD, director of gynecologic oncology at Mount Sinai Health System, said in a press release. “Too often, women are sent to a gastroenterologist or told they’re just aging when experiencing these kinds of symptoms, and by then they have lost valuable time.”

In conjunction with these observances, HemOnc Today presents five updates about screening for and treatment of gynecologic malignancies:

  • The FDA granted regular approval to olaparib (Lynparza, AstraZeneca) tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who achieved complete or partial response to platinum-based chemotherapy. Read more.
  • A second interim analysis of a trial designed to evaluate the addition of fosbretabulin (CA4P, Mateon Therapeutics) to standard therapy for patients with platinum-resistant ovarian cancer showed a small PFS benefit for the combination. Read more.
  • A clinical trial scheduled to evaluate the safety and efficacy of a bag designed to catch cancerous tissue from power morcellation in women undergoing laparoscopic hysterectomies has rekindled debate in the gynecologic community about the controversial procedure. Read more.
  • Clear cell endometrial cancer appeared to have molecular similarities with serous endometrial cancer and endometrioid endometrial cancer, according to a study published in Cancer. Additionally, TAF1 appeared to be a driver mutated gene in clear cell endometrial cancer. Read more.
  • The U.S. Preventive Services Task Force released a draft statement that recommended against screening for ovarian cancer in women who have no signs or symptoms. Read more.